clarithromycin is a lipid of Polyketides (PK) class. Clarithromycin is associated with abnormalities such as Helicobacter Pylori Infection, Infection, Coinfection, Gastritis and Peptic Ulcer. The involved functions are known as Point Mutation, Increased Sensitivy, Bacterial resistance, urease activity and Mutation. Clarithromycin often locates in Blood, Gastric mucosa, Biopsy sample, Respiratory System and Entire gastrointestinal tract. The associated genes with clarithromycin are Genes, rRNA, rRNA Operon, Genome, HM13 gene and GDF15 gene. The related lipids are 9,11-linoleic acid, Steroids, Lysophosphatidylcholines, Lipopolysaccharides and 4-hydroxycholesterol. The related experimental models are Mouse Model, Knock-out and Experimental Pneumococcal Meningitis.
To understand associated biological information of clarithromycin, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
clarithromycin is suspected in Infection, Helicobacter Pylori Infection, Pneumonia, Respiratory Tract Infections, PARKINSON DISEASE, LATE-ONSET, Community acquired pneumonia and other diseases in descending order of the highest number of associated sentences.
Disease | Cross reference | Weighted score | Related literature |
---|
We collected disease MeSH terms mapped to the references associated with clarithromycin
There are no associated biomedical information in the current reference collection.
Associated locations are in red color. Not associated locations are in black.
Location | Cross reference | Weighted score | Related literatures |
---|
Function | Cross reference | Weighted score | Related literatures |
---|
Lipid concept | Cross reference | Weighted score | Related literatures |
---|
Gene | Cross reference | Weighted score | Related literatures |
---|
Mouse Model are used in the study 'Inflammation provoked by Mycoplasma pneumoniae extract: implications for combination treatment with clarithromycin and dexamethasone.' (Hirao S et al., 2011), Mouse Model are used in the study 'Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers.' (Hafner R et al., 1998), Mouse Model are used in the study 'Clarithromycin attenuates mastectomy-induced acute inflammatory response.' (Chow LW et al., 2000) and Mouse Model are used in the study 'In vitro and in vivo influence of adjunct clarithromycin on the treatment of mucoid Pseudomonas aeruginosa.' (Bui KQ et al., 2000).
Knock-out are used in the study 'Intrinsic macrolide resistance in Mycobacterium smegmatis is conferred by a novel erm gene, erm(38).' (Nash KA, 2003).
Experimental Pneumococcal Meningitis are used in the study 'Failure of treatment for chronic Mycobacterium abscessus meningitis despite adequate clarithromycin levels in cerebrospinal fluid.' (Maniu CV et al., 2001).
Model | Cross reference | Weighted score | Related literatures |
---|
Authors | Title | Published | Journal | PubMed Link |
---|---|---|---|---|
Zhang X and Hu C | Selecting optimal columns for clarithromycin impurity analysis according to the quantitative relationship of hydrophobic subtraction model. | 2017 | J Pharm Biomed Anal | pmid:28024686 |
Addo KK et al. | Genotyping and drug susceptibility testing of mycobacterial isolates from population-based tuberculosis prevalence survey in Ghana. | 2017 | BMC Infect. Dis. | pmid:29197331 |
Liu W et al. | Rapid detection of mutations in erm(41) and rrl associated with clarithromycin resistance in Mycobacterium abscessus complex by denaturing gradient gel electrophoresis. | 2017 | J. Microbiol. Methods | pmid:29079298 |
Koh WJ et al. | Mycobacterial Characteristics and Treatment Outcomes in Mycobacterium abscessus Lung Disease. | 2017 | Clin. Infect. Dis. | pmid:28011608 |
Chang CH et al. | Non-Tuberculous Mycobacteria Infection Following Autologous Fat Grafting on the Face. | 2017 | Aesthet Surg J | pmid:29045552 |
Çekin AH et al. | Use of probiotics as an adjuvant to sequential H. pylori eradication therapy: impact on eradication rates, treatment resistance, treatment-related side effects, and patient compliance. | 2017 | Turk J Gastroenterol | pmid:28007678 |
Ikeue T et al. | Pleuritis Caused by Mycobacterium kyorinense without Pulmonary Involvement. | 2017 | Intern. Med. | pmid:28924121 |
Panozzo C et al. | Chemicals or mutations that target mitochondrial translation can rescue the respiratory deficiency of yeast bcs1 mutants. | 2017 | Biochim. Biophys. Acta | pmid:28888990 |
Emmanuel R et al. | Antimicrobial efficacy of drug blended biosynthesized colloidal gold nanoparticles from Justicia glauca against oral pathogens: A nanoantibiotic approach. | 2017 | Microb. Pathog. | pmid:29101061 |
Larsen EL et al. | Clarithromycin, trimethoprim, and penicillin and oxidative nucleic acid modifications in humans: randomised, controlled trials. | 2017 | Br J Clin Pharmacol | pmid:28185274 |
Ono S et al. | Vonoprazan improves the efficacy of Helicobacter pylori eradication therapy with a regimen consisting of clarithromycin and metronidazole in patients allergic to penicillin. | 2017 | Helicobacter | pmid:28098408 |
Gouin-Thibault I et al. | Interindividual variability in dabigatran and rivaroxaban exposure: contribution of ABCB1 genetic polymorphisms and interaction with clarithromycin. | 2017 | J. Thromb. Haemost. | pmid:27893182 |
Park J et al. | Progression and Treatment Outcomes of Lung Disease Caused by Mycobacterium abscessus and Mycobacterium massiliense. | 2017 | Clin. Infect. Dis. | pmid:28011609 |
Park SM et al. | Randomized clinical trial comparing 10- or 14-day sequential therapy and 10- or 14-day concomitant therapy for the first line empirical treatment of Helicobacter pylori infection. | 2017 | J. Gastroenterol. Hepatol. | pmid:27505301 |
Ishiguro N et al. | Therapeutic efficacy of azithromycin, clarithromycin, minocycline and tosufloxacin against macrolide-resistant and macrolide-sensitive Mycoplasma pneumoniae pneumonia in pediatric patients. | 2017 | PLoS ONE | pmid:28288170 |
Attaran B et al. | Effect of biofilm formation by clinical isolates of on the efflux-mediated resistance to commonly used antibiotics. | 2017 | World J. Gastroenterol. | pmid:28275296 |
Chang CT et al. | Antibiotic treatment of zebrafish mycobacteriosis: tolerance and efficacy of treatments with tigecycline and clarithromycin. | 2017 | J. Fish Dis. | pmid:28422304 |
Furuya H et al. | SAPHO syndrome-like presentation of disseminated nontuberculous mycobacterial infection in a case with neutralizing anti-IFNγ autoantibody. | 2017 | Rheumatology (Oxford) | pmid:28371927 |
Ye JF et al. | Evaluation of first-line bismuth-containing 7-day concomitant quintuple therapy for Helicobacter pylori eradication. | 2017 | J Dig Dis | pmid:29119724 |
Chang KH et al. | Comparison of antibiotic regimens in preterm premature rupture of membranes: neonatal morbidity and 2-year follow-up of neurologic outcome. | 2017 | J. Matern. Fetal. Neonatal. Med. | pmid:27687157 |
Liatsos C and Leontiadis GII | The "report card" to grade H. Pylori treatment regimens: is it achievable in real-world in areas with high clarithromycin resistance? | 2017 | J Gastrointestin Liver Dis | pmid:28617893 |
Chew CA et al. | The diagnosis and management of H. pylori infection in Singapore. | 2017 | Singapore Med J | pmid:28536725 |
Gunnarsdottir AI et al. | Antibiotic susceptibility of Helicobacter pylori in Iceland. | 2017 | Infect Dis (Lond) | pmid:28440099 |
Oikawa R et al. | Enrichment of Helicobacter pylori mutant strains after eradication therapy analyzed by gastric wash-based quantitative pyrosequencing. | 2017 | Tumour Biol. | pmid:28990461 |
Radzikowska E et al. | Cryptogenic organizing pneumonia-Results of treatment with clarithromycin versus corticosteroids-Observational study. | 2017 | PLoS ONE | pmid:28945804 |
Chew KL et al. | Predominance of clarithromycin-susceptible Mycobacterium massiliense subspecies: Characterization of the Mycobacterium abscessus complex at a tertiary acute care hospital. | 2017 | J. Med. Microbiol. | pmid:28874233 |
Anwar HF et al. | Synthesis of clarithromycin ketolides chemically modified at the unreactive C10-methyl group. | 2017 | Bioorg. Med. Chem. | pmid:28302508 |
Turvey SL et al. | Mycobacterium branderi infection: Case report and literature review of an unusual and difficult-to-treat non-tuberculous mycobacterium. | 2017 | Int. J. Infect. Dis. | pmid:28268125 |
Kadota JI et al. | The clinical efficacy of a clarithromycin-based regimen for Mycobacterium avium complex disease: A nationwide post-marketing study. | 2017 | J. Infect. Chemother. | pmid:28254517 |
Quinn KL et al. | Macrolides, Digoxin Toxicity and the Risk of Sudden Death: A Population-Based Study. | 2017 | Drug Saf | pmid:28421551 |
Ramzy I et al. | GENETIC MUTATIONS AFFECTING THE FIRST LINE ERADICATION THERAPY OF Helicobacter pylori-INFECTED EGYPTIAN PATIENTS. | 2016 | Rev. Inst. Med. Trop. Sao Paulo | pmid:27982354 |
Kasai C et al. | Changes in plasma ghrelin and leptin levels in patients with peptic ulcer and gastritis following eradication of Helicobacter pylori infection. | 2016 | BMC Gastroenterol | pmid:27716077 |
Ferro BE et al. | Failure of the Amikacin, Cefoxitin, and Clarithromycin Combination Regimen for Treating Pulmonary Mycobacterium abscessus Infection. | 2016 | Antimicrob. Agents Chemother. | pmid:27458221 |
Patton PH et al. | Anti-tuberculous therapy for maintenance of remission in Crohn's disease. | 2016 | Cochrane Database Syst Rev | pmid:27444319 |
Christl I et al. | Clarithromycin and Tetracycline Binding to Soil Humic Acid in the Absence and Presence of Calcium. | 2016 | Environ. Sci. Technol. | pmid:27438991 |
Laird-Fick HS et al. | Gastric adenocarcinoma: the role of Helicobacter pylori in pathogenesis and prevention efforts. | 2016 | Postgrad Med J | pmid:27222587 |
Xu J et al. | Preparation, characterization and pharmacokinetics evaluation of clarithromycin-loaded Eudragit(®) L-100 microspheres. | 2016 | Eur J Drug Metab Pharmacokinet | pmid:25652786 |
Berende A et al. | Randomized Trial of Longer-Term Therapy for Symptoms Attributed to Lyme Disease. | 2016 | N. Engl. J. Med. | pmid:27028911 |
D'Erme AM et al. | Successful treatment of rosacea fulminans in a 59-year-old woman with macrolide antibiotics and prednisone. | 2016 | Int. J. Dermatol. | pmid:27028670 |
Belz D et al. | Mycobacterium marinum infection initially diagnosed as metastatic Crohn's disease. | 2016 | J Eur Acad Dermatol Venereol | pmid:25510444 |
Song Z et al. | Levofloxacin, bismuth, amoxicillin and esomeprazole as second-line Helicobacter pylori therapy after failure of non-bismuth quadruple therapy. | 2016 | Dig Liver Dis | pmid:26847964 |
Vannarath S et al. | Antibiotic Resistant Pattern of Helicobacter Pylori Infection Based on Molecular Tests in Laos. | 2016 | Asian Pac. J. Cancer Prev. | pmid:26838225 |
Miyamoto S et al. | Analysis of Helicobacter pylori genotypes in clinical gastric wash samples. | 2016 | Tumour Biol. | pmid:26825980 |
Konstantinidis T et al. | Immunomodulatory Role of Clarithromycin in Acinetobacter baumannii Infection via Formation of Neutrophil Extracellular Traps. | 2016 | Antimicrob. Agents Chemother. | pmid:26643338 |
Ferro BE et al. | Clofazimine Prevents the Regrowth of Mycobacterium abscessus and Mycobacterium avium Type Strains Exposed to Amikacin and Clarithromycin. | 2016 | Antimicrob. Agents Chemother. | pmid:26643335 |
Wu TS et al. | Postcesarean section wound infection caused by Mycobacterium massiliense. | 2016 | J Microbiol Immunol Infect | pmid:26350122 |
Senatore FJ et al. | Helicobacter pylori treatment: Still a work in progress. | 2016 | Postgrad Med | pmid:26490697 |
Narita M et al. | Antimicrobial Susceptibility of Microorganisms Isolated from Periapical Periodontitis Lesions. | 2016 | Bull. Tokyo Dent. Coll. | pmid:27665691 |
Yoon H et al. | Effects of N-acetylcysteine on First-Line Sequential Therapy for Helicobacter pylori Infection: A Randomized Controlled Pilot Trial. | 2016 | Gut Liver | pmid:26347514 |
Liou JM et al. | Sequential therapy for 10 days versus triple therapy for 14 days in the eradication of in the community and hospital populations: a randomised trial. | 2016 | Gut | pmid:26338825 |